Fig. 3.
Effect of EET-agonist on the levels of PPARγ, FAS, Wnt/β-catenin and pACC. (A) hMSCs-derived adipocytes expressed elevated levels of PPARγ and FAS. Western blots showed that EET-agonist sustained decrease in PPARγ and FAS and simultaneous decrease in β-catenin and pACC. (B) Densitometric evaluations of protein were obtained from three different experiments. Data are expressed as mean ± SE (*p < 0.05 versus untreated 2 days MSCs-derived adipocyte growth). (C) adipogenic markers including PPARγ and SREBP-1 mRNA expression analyzed by quantitative PCR in 10 days culture treated and untreated with EET-agonist. Results for each condition are expressed as mean ± SE (n = 6, *p < 0.05 versus EET-agonist treated).